Pharmafile Logo
Pharmafocus logo
Advanced Search

NHS struggles to meet targets as more demand for services grows

March 18, 2019
Sales and Marketing A&E, NHS, hospitals

The NHS is struggling to meet targets as the health service is being used by more patients than ever before, …

News

NICE to set out new opioid prescription guidelines for GPs

March 18, 2019
Sales and Marketing GPs, NICE, addiction, addictive drugs, opioids, prescription drugs, withdrawal

NICE is set to develop new guidelines for GPs and healthcare professionals setting out rules for doctors regarding opioids and …

News
heart-2372134_640

Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk

March 18, 2019
Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …

News
920x920

Purdue Pharma vow not to profit from fast tracked opioid overdose antidote

March 18, 2019
Sales and Marketing FDA, OxyContin, Purdue Pharma, nalmefene hydrochloride, opioids

The FDA has granted OxyContin drugmaker Purdue Pharma, fast track designation for opioid overdose antidote nalmefene hydrochloride (HCl) injection. However, …

News
mr058666-web

Merck KGaA enters drug discovery partnership with AI firm Itkos

March 15, 2019
Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma

Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …

News
norman_sharpless_official_photo

National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner

March 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …

Appointment
richard-francis-big-image_0

Sandoz CEO Richard Francis to step down

March 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …

Appointment
images

Roche scores two EU approvals in haemophilia and rare autoimmune disease

March 15, 2019
Medical Communications EC, EU, Europe, Roche, haemophilia, rare diseases

The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera …

News
merckwindow_web

MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer

March 15, 2019
Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Acadia Pharmaceuticals, FDA, Sandoz, brexit, genomics, pharma, pharmacovigilance, top 10

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …

News
ianread

Pfizer CEO Ian Read’s pay packet cut from $27.9m to $19.5m

March 15, 2019
Medical Communications CEO, Ian Read, Pfizer, compensation, pay packet, salary

Ian Read has seen his total compensation cut from a sum of $27.9 million in 2018 to $19.5 million this …

News
roche_dark_0

Roche and Chugai’s Hemlibra scoops up EU approval in the prevention of severe haemophilia A without factor VIII inhibitors

March 14, 2019
Sales and Marketing Chugai, Hemlibra, Roche, haemophilia, pharma

Roche has announced along with its partner Chugai that Hemlibra (emicizumab) has secured approval from the European Commission as a …

News
celgene_building

Celgene’s Abraxane combo flops in phase 3 cancer trials

March 14, 2019
Research and Development Abraxane, Celgene, clinical trials, pharma, trials

Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …

News
ent-cholesterol_molecule_spacefill

New class of drugs offer alternative to statins

March 14, 2019
Research and Development cholesterol, health, imperial college london, research, statins

A new class of cholesterol lowering drugs may help patients who are unable to take statins, according to a study …

News
richard-francis-big-image

Sandoz CEO Richard Francis to step down

March 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …

News

Califonia court rules J&J must pay woman with mesothelioma $29 million

March 14, 2019
Medical Communications, Sales and Marketing

A California jury has ordered American healthcare conglomerate Johnson & Johnson to pay more than $29 million to a woman …

News
norman_sharpless_official_photo

National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner

March 13, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Ned Sharpless, Scott Gottlieb, appointment, pharma

Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …

News
janssen_latest_logo_on_sign_closer

Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

March 13, 2019
Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …

News
lilly_building_with_american_flag_web

Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment

March 13, 2019
Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …

News
28246711066_52e38bc591_z

Healthcare industry could take up to five years to stabilise after no-deal Brexit

March 13, 2019
Manufacturing and Production, Medical Communications, Research and Development GlobalData, analysis, brexit, no-deal Brexit, surveys

The healthcare industry could take up to five years to stabilise in the event of a no-deal Brexit, according to …

News
The Gateway to Local Adoption Series

Latest content

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026